Unknown

Dataset Information

0

Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

ABSTRACT: To search for new therapies aimed at ameliorating the neurologic symptoms and epilepsy developing in patients with Lafora disease.Lafora disease is caused by loss-of-function mutations in either the EPM2A or EPM2B genes. Epm2a-/- and Epm2b-/- mice display neurologic and behavioral abnormalities similar to those found in patients. Selenium is a potent antioxidant and its deficiency has been related to the development of certain diseases, including epilepsy. In this study, we investigated whether sodium selenate treatment improved the neurologic alterations and the hyperexcitability present in the Epm2b-/- mouse model.Sodium selenate ameliorates some of the motor and memory deficits and the sensitivity observed with pentylenetetrazol (PTZ) treatments in Epm2b-/- mice. Neuronal degeneration and gliosis were also diminished after sodium selenate treatment.Sodium selenate could be beneficial for ameliorating some symptoms that present in patients with Lafora disease.

SUBMITTER: Sanchez-Elexpuru G 

PROVIDER: S-EPMC5495962 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

Sánchez-Elexpuru Gentzane G   Serratosa José M JM   Sánchez Marina P MP  

Epilepsia 20170118 3

<h4>Objective</h4>To search for new therapies aimed at ameliorating the neurologic symptoms and epilepsy developing in patients with Lafora disease.<h4>Methods</h4>Lafora disease is caused by loss-of-function mutations in either the EPM2A or EPM2B genes. Epm2a<sup>-/-</sup> and Epm2b<sup>-/-</sup> mice display neurologic and behavioral abnormalities similar to those found in patients. Selenium is a potent antioxidant and its deficiency has been related to the development of certain diseases, inc  ...[more]

Similar Datasets

Unknown Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
| S-EPMC3408169 | biostudies-literature
Unknown Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
| S-EPMC5472678 | biostudies-literature
Unknown Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy.
| S-EPMC9844227 | biostudies-literature
Unknown Deciphering the role of malin in the lafora progressive myoclonus epilepsy.
| S-EPMC3458166 | biostudies-literature
Unknown Malin restoration as proof of concept for gene therapy for Lafora disease.
| S-EPMC9260307 | biostudies-literature
Unknown Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
| S-EPMC2801266 | biostudies-literature
Unknown Sodium selenate regulates the brain ionome in a transgenic mouse model of Alzheimer's disease.
| S-EPMC5180247 | biostudies-literature
Unknown Spontaneous seizures and elevated seizure susceptibility in response to somatic mutation of sodium channel Scn8a in the mouse.
| S-EPMC8165645 | biostudies-literature
Unknown Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
| S-EPMC5474477 | biostudies-literature
Unknown P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease.
| S-EPMC10682699 | biostudies-literature